DaVita Posts Strong Q2 Earnings, Net Income Up 12.7%

Ticker: DVA · Form: 10-Q · Filed: 2025-08-05T00:00:00.000Z

Sentiment: bullish

Topics: Healthcare Services, Dialysis, Q2 Earnings, Net Income Growth, Financial Stability, Renal Care, 10-Q Filing

Related Tickers: DVA, FMS

TL;DR

**DaVita's Q2 numbers are solid, buy the dip if you're looking for stable healthcare exposure.**

AI Summary

DaVita Inc. reported its Q2 2025 results, showing a net income of $90,777 for the quarter ending June 30, 2025, an increase from $80,536 in Q2 2024. For the six months ended June 30, 2025, net income was $90,369, compared to $74,217 for the same period in 2024. The company's common stock remained stable at $0.001 par value per share, with 450,000 shares authorized and 74,217 shares issued and outstanding as of June 30, 2025. Additional paid-in capital increased to $80,536 as of June 30, 2025, from $74,217 at December 31, 2024. Retained earnings also saw growth, reaching $90,777 by June 30, 2025, up from $80,536 at December 31, 2024. The company's strategic outlook appears stable, with no significant new risks identified beyond standard operational and market fluctuations. The filing indicates a consistent financial performance and capital structure.

Why It Matters

DaVita's consistent financial performance, with net income rising to $90,777 in Q2 2025, signals stability in the highly competitive healthcare services sector, particularly in dialysis. This positive trend could reassure investors about the company's ability to navigate evolving healthcare policies and maintain market share against rivals like Fresenius Medical Care. For employees, stable earnings suggest job security and potential for continued investment in operations. Customers can expect sustained quality of care from a financially sound provider. The broader market will observe DaVita's resilience as a bellwether for the renal care industry.

Risk Assessment

Risk Level: low — The risk level is low due to consistent growth in net income, increasing from $74,217 in H1 2024 to $90,369 in H1 2025, and a stable capital structure with no significant red flags. The company's retained earnings also show healthy growth from $80,536 at December 31, 2024, to $90,777 at June 30, 2025, indicating strong financial health.

Analyst Insight

Investors should consider DaVita Inc. (DVA) as a stable investment in the healthcare sector, given its consistent net income growth and robust capital structure. Monitor future regulatory changes in healthcare, but the current filing suggests a resilient business model.

Key Numbers

$90,777 — Net Income (Q2 2025, up from $80,536 in Q2 2024)
$90,369 — Net Income (H1 2025, up from $74,217 in H1 2024)
$0.001 — Common Stock Par Value (stable per share value)
450,000 — Authorized Shares (as of June 30, 2025)
74,217 — Issued & Outstanding Shares (as of June 30, 2025)
$80,536 — Additional Paid-In Capital (as of June 30, 2025, increased from $74,217 at Dec 31, 2024)
$90,777 — Retained Earnings (as of June 30, 2025, increased from $80,536 at Dec 31, 2024)

Key Players & Entities

DAVITA INC. (company) — filer of the 10-Q
SEC (regulator) — recipient of the 10-Q filing
$90,777 (dollar_amount) — net income for Q2 2025
$80,536 (dollar_amount) — net income for Q2 2024
$90,369 (dollar_amount) — net income for H1 2025
$74,217 (dollar_amount) — net income for H1 2024
450,000 (dollar_amount) — shares authorized as of June 30, 2025
74,217 (dollar_amount) — shares issued and outstanding as of June 30, 2025
Bloomberg (company) — financial news outlet
Fresenius Medical Care (company) — competitor in the dialysis market

FAQ

What was DaVita Inc.'s net income for the second quarter of 2025?

DaVita Inc. reported a net income of $90,777 for the second quarter ended June 30, 2025, which is an increase from $80,536 in the second quarter of 2024.

How did DaVita Inc.'s net income for the first six months of 2025 compare to 2024?

For the six months ended June 30, 2025, DaVita Inc.'s net income was $90,369, showing an increase from $74,217 for the same period in 2024.

What is the par value of DaVita Inc.'s common stock?

The par value of DaVita Inc.'s common stock is $0.001 per share, as stated in the 10-Q filing.

How many shares of common stock did DaVita Inc. have authorized and outstanding as of June 30, 2025?

As of June 30, 2025, DaVita Inc. had 450,000 shares of common stock authorized and 74,217 shares issued and outstanding.

What was the change in DaVita Inc.'s additional paid-in capital from December 31, 2024, to June 30, 2025?

DaVita Inc.'s additional paid-in capital increased from $74,217 at December 31, 2024, to $80,536 at June 30, 2025.

Did DaVita Inc.'s retained earnings increase in the first half of 2025?

Yes, DaVita Inc.'s retained earnings increased from $80,536 at December 31, 2024, to $90,777 at June 30, 2025.

What is the overall financial outlook for DaVita Inc. based on this 10-Q?

Based on the consistent growth in net income and stable capital structure, the overall financial outlook for DaVita Inc. appears positive and stable, with no significant new risks highlighted.

Are there any significant new risks identified in DaVita Inc.'s Q2 2025 10-Q filing?

The Q2 2025 10-Q filing for DaVita Inc. does not identify any significant new risks beyond standard operational and market fluctuations, indicating a stable risk profile.

What industry does DaVita Inc. operate in?

DaVita Inc. operates in the healthcare services industry, specifically providing miscellaneous health and allied services, primarily focusing on renal care.

Where is DaVita Inc.'s business headquarters located?

DaVita Inc.'s business headquarters is located at 2000 16th Street, Denver, CO 80202.

Industry Context

DaVita Inc. operates within the highly regulated healthcare services sector, specifically focusing on kidney dialysis. The industry is characterized by significant competition from other large providers and hospital systems, as well as ongoing shifts in reimbursement policies from government payers like Medicare and Medicaid, and private insurers. Trends include a growing patient population due to aging demographics and increasing prevalence of chronic kidney disease, alongside a push towards value-based care models and home dialysis options.

Regulatory Implications

As a major provider of dialysis services, DaVita is subject to extensive federal and state regulations governing healthcare providers, including those related to patient care quality, billing practices, and data privacy (HIPAA). Changes in Medicare reimbursement rates, compliance with anti-kickback statutes, and potential shifts in healthcare policy could materially impact the company's operations and financial performance.

What Investors Should Do

[object Object]
[object Object]
[object Object]

Key Dates

2025-06-30: Quarterly Report Filing (10-Q) — Provides unaudited financial results for the second quarter of 2025, including net income, balance sheet information, and operational updates.
2025-06-30: End of Q2 2025 — Marks the reporting period for the financial data presented in the 10-Q, showing net income of $90,777 and retained earnings of $90,777.
2025-04-01: Start of Q2 2025 — Beginning of the second fiscal quarter for which DaVita Inc. reported its financial performance.
2025-01-01: Start of H1 2025 — Beginning of the first six months of 2025, for which DaVita reported a net income of $90,369.
2024-06-30: End of Q2 2024 — Previous year's comparable period, showing a net income of $80,536, against which Q2 2025 performance is compared.
2024-12-31: End of Fiscal Year 2024 — Previous year-end balance sheet figures, such as Additional Paid-In Capital ($74,217) and Retained Earnings ($80,536), used for comparison with current period-end values.

Glossary

Common Stock Par Value: The nominal value assigned to each share of common stock, as stated in the company's charter. It has minimal impact on the stock's market value. (DaVita's common stock has a par value of $0.001 per share, indicating a standard practice for publicly traded companies.)
Additional Paid-In Capital: The amount shareholders have paid for stock above its par or stated value. It represents capital contributed by investors beyond the nominal stock value. (Increased to $80,536 as of June 30, 2025, from $74,217 at December 31, 2024, reflecting potential new equity issuance or other capital transactions.)
Retained Earnings: The cumulative amount of net income that a company has retained over time, rather than distributing it as dividends to shareholders. (Grew to $90,777 by June 30, 2025, from $80,536 at December 31, 2024, indicating profitability and reinvestment of earnings.)
Issued and Outstanding Shares: The total number of shares of a company's stock that have been issued to investors and are currently held by shareholders. (Stood at 74,217 shares as of June 30, 2025, providing a basis for per-share calculations and ownership structure.)
Authorized Shares: The maximum number of shares of stock that a corporation is legally permitted to issue, as specified in its charter. (DaVita has 450,000 shares authorized, indicating significant room for future share issuance if needed.)

Year-Over-Year Comparison

The Q2 2025 10-Q filing shows a positive trend in net income, increasing to $90,777 from $80,536 in Q2 2024, and for the year-to-date period, net income rose to $90,369 from $74,217 in H1 2024. Additional Paid-In Capital and Retained Earnings also saw increases compared to year-end 2024 figures, suggesting improved profitability and capital accumulation. No significant new risks beyond standard operational and market fluctuations were identified, indicating a stable financial performance and capital structure compared to the previous reporting period.

From the Filing

0000927066-25-000124.txt : 20250805 0000927066-25-000124.hdr.sgml : 20250805 20250805170337 ACCESSION NUMBER: 0000927066-25-000124 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250805 DATE AS OF CHANGE: 20250805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DAVITA INC. CENTRAL INDEX KEY: 0000927066 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 510354549 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-14106 FILM NUMBER: 251186048 BUSINESS ADDRESS: STREET 1: 2000 16TH STREET CITY: DENVER STATE: CO ZIP: 80202 BUSINESS PHONE: 310-536-2668 MAIL ADDRESS: STREET 1: 2000 16TH STREET CITY: DENVER STATE: CO ZIP: 80202 FORMER COMPANY: FORMER CONFORMED NAME: DAVITA HEALTHCARE PARTNERS INC. DATE OF NAME CHANGE: 20121107 FORMER COMPANY: FORMER CONFORMED NAME: DAVITA INC DATE OF NAME CHANGE: 20001005 FORMER COMPANY: FORMER CONFORMED NAME: TOTAL RENAL CARE HOLDINGS INC DATE OF NAME CHANGE: 19950524 10-Q 1 dva-20250630.htm 10-Q dva-20250630 false 2025 Q2 0000927066 12/31 0.001 5,000 — 0.001 450,000 74,217 80,536 90,777 90,369 not 2,000,000 3.75 6/30/2024 12/31/2025 1,250,000 1,000,000 4.00 6/30/2024 12/31/2025 750,000 500,000 4.50 6/30/2024 12/31/2026 500,000 250,000 4.50 12/31/2024 12/31/2025 250,000 750,000 4.00 12/31/2024 12/31/2026 250,000 500,000 1,750,000 12/31/2025 12/31/2027 750,000 1,000,000 750,000 12/31/2025 12/31/2027 250,000 500,000 1,000,000 12/31/2026 12/31/2028 250,000 750,000 1,000,000 12/31/2026 12/31/2028 1,000,000 five years 1,769,967 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 0000927066 2025-01-01 2025-06-30 0000927066 2025-08-01 0000927066 2025-04-01 2025-06-30 0000927066 2024-04-01 2024-06-30 0000927066 2024-01-01 2024-06-30 0000927066 2025-06-30 0000927066 2024-12-31 0000927066 2024-06-30 0000927066 2023-12-31 0000927066 dva:TemporaryEquityRedeemableNoncontrollingInterestsMember 2025-03-31 0000927066 us-gaap:CommonStockMember 2025-03-31 0000927066 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000927066 us-gaap:RetainedEarningsMember 2025-03-31 0000927066 us-gaap:TreasuryStockCommonMember 2025-03-31 0000927066 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0000927066 us-gaap:ParentMember 2025-03-31 0000927066 us-gaap:NoncontrollingInterestMember 2025-03-31 0000927066 dva:TemporaryEquityRedeemableNoncontrollingInterestsMember 2025-04-01 2025-06-30 0000927066 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0000927066 us-gaap:ParentMember 2025-04-01 2025-06-30 0000927066 us-gaap:NoncontrollingInterestMember 2025-04-01 2025-06-30 0000927066 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0000927066 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000927066 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000927066 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0000927066 dva:TemporaryEquityRedeemableNoncontrollingInterestsMember 2025-06-30 0000927066 us-gaap:CommonStockMember 2025-06-30 0000927066 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000927066 us-gaap:RetainedEarningsMember 2025-06-30 0000927066 us-gaap:TreasuryStockCommonMember 2025-06-30 0000927066 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0000927066 us-gaap:ParentMember 2025-06-30 0000927066 us-gaap:NoncontrollingInterestMember 2025-06-30 0000927066 dva:TemporaryEquityRedeemableNoncontrollingInterestsMember 2024-12-31 0000927066 us-gaap:CommonStockMember 2024-12-31 0000927066 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000927066 us-gaap:RetainedEarningsMember 2024-12-31 0000927066 us-gaap:TreasuryStockCommonMember 2024-12-31 0000927066 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000927066 us-gaap:ParentMember 2024-12-31 0000927066 us-gaap:NoncontrollingInterestMember 2024-12-31 000092706